Renaissance Capital logo

Calyxt Priced, Nasdaq: CLXT

Developer of gene-edited crop traits spun out of Cellectis.

Industry: Health Care

First Day Return: +40.6%

Industry: Health Care

We are a consumer-centric, food- and agriculture-focused company. By combining our leading gene-editing technology and technical expertise with our innovative commercial strategy, we are pioneering a paradigm shift to deliver healthier specialty food ingredients, such as healthier oils and high fiber wheat, for consumers and agriculturally advantageous crop traits, such as herbicide tolerance, to farmers. While the traits that enable these characteristics may occur naturally and randomly through evolution -- or under a controlled environment through traditional agricultural technologies -- those processes are imprecise and take many years, if not decades. Our technology enables us to precisely and specifically edit a plant genome to elicit the desired traits and characteristics, resulting in a final product that has no foreign DNA. We believe the precision, specificity, cost effectiveness and development speed of our gene-editing technologies will enable us to provide meaningful disruption to the food and agriculture industries.
more less
IPO Data
IPO File Date 06/23/2017
Offer Price $8.00
Price Range $8.00 - $10.00
Offer Shares (mm) 7.0
Deal Size ($mm) $56
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 07/19/2017
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $56
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters New Brighton, MN, United States
Founded 2010
Employees at IPO 27
Website www.calyxt.com

Calyxt (CLXT) Performance